AAA
IMVT icon

Affinity Asset Advisors’s Immunovant IMVT Stock Holding History

Affinity Asset Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-128,100
Closed -$4.92M – 90
2023
Q3 		$4.92M Buy
+128,100
New +$2.9M 1.38% 25

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Affinity Asset Advisors's IMVT Position: Q1 2026 in Review

Affinity Asset Advisors reduced its Immunovant (IMVT) stake by 50% in Q1 2026, selling an estimated $2.59M and leaving 100,000 shares worth $2.48M. The position accounts for 0.13% of the portfolio, ranked #91.

Affinity Asset Advisors first reported a position in IMVT in Q4 2020 and has held it in 12 quarters since. The position peaked at $14.5M in Q4 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Affinity Asset Advisors held 100,000 shares of Immunovant worth $2.48M as of Q1 2026.
  • Affinity Asset Advisors sold 100,000 Immunovant shares in Q1 2026, an estimated $2.59M.
  • Immunovant made up 0.13% of Affinity Asset Advisors's portfolio in Q1 2026, its #91 holding.
  • Affinity Asset Advisors first reported a position in Immunovant in Q4 2020 and has held it in 12 quarters since.
  • Affinity Asset Advisors's Immunovant position peaked at $14.5M in Q4 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Affinity Asset Advisors's 13F filing for Q1 2026, filed 14 May 2026.